Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Clinical Outlook
  • Published:

The shifting treatment paradigm of metastatic renal cell carcinoma

Nature Reviews Urology volume 19, pages 631–632 (2022)Cite this article

Subjects

The treatment landscape of renal cell carcinoma is rapidly evolving, especially with the introduction and approval of immune checkpoint inhibitor combination therapies. Clinical trial data show substantial improvements in patient outcomes, and now results in the real-world setting support the use of these combinations.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Dramatic treatment response to systemic therapy in metastatic renal cell carcinoma.

References

  1. Choueiri, T. K. & Motzer, R. J. Systemic therapy for metastatic renal-cell carcinoma. N. Engl. J. Med. 376, 354–366 (2017).

    Article  CAS  PubMed  Google Scholar 

  2. Motzer, R. J. et al. Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J. Natl Compr. Canc. Netw. 20, 71–90 (2022).

    Article  PubMed  Google Scholar 

  3. Zambrana, F. et al. Complete response and renal cell carcinoma in the immunotherapy era: the paradox of good news. Cancer Treat. Rev. 99, 102239 (2021).

    Article  CAS  PubMed  Google Scholar 

  4. Motzer, R. et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N. Engl. J. Med. 384, 1289–1300 (2021).

    Article  CAS  PubMed  Google Scholar 

  5. Bartlett, V. L., Dhruva, S. S., Shah, N. D., Ryan, P. & Ross, J. S. Feasibility of using real-world data to replicate clinical trial evidence. JAMA Netw. Open 2, e1912869 (2019).

    Article  PubMed  PubMed Central  Google Scholar 

  6. Mar, N., Kaakour, D. & Rezazadeh Kalebasty, A. Renal cell carcinoma-lessons in diversity, breakthroughs, and challenges. JCO Oncol. Pract. 18, 197–199 (2022).

    Article  PubMed  Google Scholar 

  7. Ged, Y. & Voss, M. H. Novel emerging biomarkers to immunotherapy in kidney cancer. Ther. Adv. Med. Oncol. 13, 17588359211059367 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Braun, D. A. et al. Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma. Nat. Rev. Clin. Oncol. 18, 199–214 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Choueiri, T. K. & Kaelin, W. G. Jr. Targeting the HIF2–VEGF axis in renal cell carcinoma. Nat. Med. 26, 1519–1530 (2020).

    Article  CAS  PubMed  Google Scholar 

  10. Choueiri, T. K. et al. Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis. Nat. Med. 27, 802–805 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Yasser Ged & Mark C. Markowski

  2. The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Nirmish Singla

  3. The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Steven P. Rowe

Authors
  1. Yasser Ged
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark C. Markowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nirmish Singla
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Steven P. Rowe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yasser Ged.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ged, Y., Markowski, M.C., Singla, N. et al. The shifting treatment paradigm of metastatic renal cell carcinoma. Nat Rev Urol 19, 631–632 (2022). https://doi.org/10.1038/s41585-022-00651-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41585-022-00651-9

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer